Andy Chen is a Hematology physician affiliated with Oregon Health & Science University. OpenAlex indexes 71 publications with 824 citations (h-index 14).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3181 SW Sam Jackson Park Rd # Uhn73c
Portland, OR 972393011
Telephone
503-494-5058Registry record last updated 22 Mar 2018.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- BeOne Medicines USA, Inc.Program year20251 payment
- ADC Therapeutics America, Inc.Program year20248 payments
- Pierre Fabre Pharmaceuticals, Inc.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
43.8%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor43.8%Acyclovir100%Part D≥33 patientsMetabolism & gastrointestinal
14.3%Serotonin-3 Receptor Antagonist6.2%Ondansetron Odt100%Part D≥14 patientsPotassium supplement4%Potassium Chloride100%Part D<11 patients+ 1 more class in this area
Cancer & immunology
10.3%Kinase inhibitor10.3%Brukinsa61%Calquence39%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A unified genetic perturbation language for human cellular programming
bioRxiv (Cold Spring Harbor Laboratory)
2025 - Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: A CIBMTR Analysis
Biology of Blood and Marrow Transplantation
2025 - POSTER: IBCL-1066 ELARA Phase 2 Clinical Outcomes for Tisagenlecleucel in Patients With High-Risk Relapsed/Refractory Follicular Lymphoma: 4-Year Update
Clinical Lymphoma Myeloma & Leukemia
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Eric Orwoll, MD
Oregon Health & Science University
Aaron Caughey, MD
Oregon Health & Science University
Tomasz Beer, MD
Oregon Health & Science University
John Nutt, MD
Oregon Health & Science University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”